Determining the best treatment course for patients with multiple myeloma
Dec 15, 2023
In a sea of new multiple myeloma treatment options, Shaji Kumar, M.D., hematologist at Mayo Clinic in Rochester, Minnesota, recommends taking the long view: Both initial and subsequent treatments should be selected bearing in mind what may be coming in the future for the patient’s disease. In presentations at the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, he proposed overall principles for assessment and treatment goals as well as selection of therapeutic options, and looked toward the future of multiple myeloma disease management.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M.Read more…